

Invitation

Stockholm April 22, 2022

Invitation to the presentation of Bactiguard's interim report for the first quarter and ahead of the AGM 2022

Bactiguard Holding AB (publ) publishes the interim report for the first quarter of 2022 on Wednesday, April 27, 2022, at 08.00 and holds the Annual General Meeting via postal vote on April 29, 2022.

In connection with this, an audiocast for shareholders, investors and analysts will be held at 11:00 CET on April 27. CEO Anders Göransson and CFO Gabriella Björknert Caracciolo will present the interim report and answer questions. The report and a presentation for the audiocast will be available at Bactiguard's website www.bactiguard.com.

To participate in the webcast, please use this link:

www.bactiguard.com/Q1-2022

To participate only by conference call, please dial:

SE: +46850558350, UK: +443333009030, US: +16467224902

Questions can be asked either in writing via the audiocast or orally if you attend the conference call.

For more information, please contact:

Gabriella Björknert Caracciolo, CFO and deputy CEO, mobile: +46 72 141 62 49

About Bactiguard

Bactiguard is a Swedish medical device company with a mission to save lives. To achieve this mission, we develop and supply infection prevention solutions which reduce the risk of infections and the use of antibiotics. This way, we save significant costs for healthcare and the society at large.

The Bactiguard technology is based on a thin noble metal alloy coating that prevents bacterial adhesion and biofilm formation on medical devices. Bactiguard offers the technology through licence agreements and our BIP (Bactiguard Infection Protection) portfolio of products. Urinary catheters with the Bactiguard technology are market leading in the USA and Japan through our licensing partner BD, and in 2021 orthopaedic trauma implants, ZNN Bactiguard, were launched by Zimmer Biomet. Bactiguard's product portfolio also includes a non-alcoholic product line for wound care and disinfection. It effectively kills microbes while being biocompatible and tissue friendly.

Bactiguard is in a strong expansion phase in the markets in Europe, China, India, the Middle East and Southeast Asia through our own product portfolio and by establishing licensing deals in new therapy areas. Bactiguard has about 210 employees around the world. Its headquarters and one of three



Bactiguard[®]

production facilities are located in Stockholm, the other two in Malaysia. Bactiguard is listed on Nasdaq Stockholm.

Read more about Bactiguard: www.bactiguard.com

